Chen H
AstraZeneca R&D Boston, 128 Sidney Street, 02139, Cambridge, MA 02139, USA.
J Control Release. 2000 Jul 3;67(2-3):117-28. doi: 10.1016/s0168-3659(00)00199-1.
Proper stimulation of the mucosal immune system is critical for the effective protection of mucosal surfaces against colonization and invasion of infectious agents. This requires administration of vaccine antigens directly to various mucosal sites. Due to the low absorption efficiency of mucosally delivered vaccines, however, almost all of the currently marketed vaccines are administered parentally. In addition, sub-optimal immune responses are frequently induced by mucosal immunization and the use of mucosal adjuvants is commonly required. As a result, development of successful mucosal vaccines depends largely on the improvement of mucosal antigen delivery and on the discovery of new and effective mucosal adjuvants. In this review, recent advances in both areas are briefly discussed.
适当刺激黏膜免疫系统对于有效保护黏膜表面免受感染因子的定植和侵袭至关重要。这需要将疫苗抗原直接递送至各种黏膜部位。然而,由于黏膜递送疫苗的吸收效率较低,目前几乎所有上市疫苗均通过非肠道途径给药。此外,黏膜免疫常常诱导产生次优免疫反应,因此通常需要使用黏膜佐剂。因此,成功的黏膜疫苗的开发在很大程度上取决于黏膜抗原递送的改善以及新型有效黏膜佐剂的发现。在本综述中,将简要讨论这两个领域的最新进展。